CareDx Inc. (CDNA) experienced a significant after-hours plunge of 5.07% following the release of its first-quarter 2026 financial results and the announcement of a major acquisition.

The transplant diagnostics firm reported robust Q1 performance, with revenue rising 39% year-over-year to $118 million, beating analyst estimates of $104.03 million. The company also posted adjusted earnings per share of $0.34, significantly above the consensus estimate of $0.13. Furthermore, CareDx raised its full-year 2026 revenue guidance to a range of $447 million to $465 million and announced a $100 million share buyback program.

Despite these positive indicators, investor sentiment turned negative following the simultaneous announcement that CareDx has entered into an agreement to acquire Naveris, a leader in viral-mediated cancer MRD surveillance testing. The deal includes $160 million in upfront cash and potential milestone payments of up to $100 million. Market participants in the post-market session appear to be weighing the costs and integration risks of the acquisition against the strong quarterly fundamentals, leading to the sharp sell-off.